Quantitative structure-activity relationship studies on matrix metalloproteinase inhibitors: Bicyclic heteroaryl hydroxamic acid analogs

被引:10
作者
Gupta, SP [1 ]
Kumaran, S
机构
[1] Birla Inst Technol & Sci, Dept Chem, Pilani 333031, Rajasthan, India
[2] Birla Inst Technol & Sci, Dept Pharm, Pilani 333031, Rajasthan, India
关键词
quantitative structure-activity relationship; bicyclic heteroaryl hydroxamic acids; MMP inhibitors;
D O I
10.2174/157018005774479096
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
A quantitative structure-activity relationship (QSAR) study has been made on some bicyclic heteroaryl hydroxamic acid analogs acting as matrix metalloproteinase (NIMP) inhibitors. The inhibition potencies of compounds against a number of MMPs were subjected to QSAR analysis and it was found surprisingly that the most crucial property of the molecules controlling the drug action, the hydrophobicity, to be playing a negative role here in most of the cases vis-a-vis the polarizability of the molecules is shown to be conducive to the potency. Based on this, it is proposed that the active sites in most of the MMPs might be having electronic nature and, only in a few, there may be some hydrophobic sites.
引用
收藏
页码:522 / 528
页数:7
相关论文
共 37 条
[1]   Expression of matrix metalloproteinase 9 (96-kd gelatinase B) in human rheumatoid arthritis [J].
Ahrens, D ;
Koch, AE ;
Pope, RM ;
SteinPicarella, M ;
Niedbala, MJ .
ARTHRITIS AND RHEUMATISM, 1996, 39 (09) :1576-1587
[2]   Molecular recognition of protein-ligand complexes: Applications to drug design [J].
Babine, RE ;
Bender, SL .
CHEMICAL REVIEWS, 1997, 97 (05) :1359-1472
[3]   ADAMs: focus on the protease domain [J].
Black, RA ;
White, JM .
CURRENT OPINION IN CELL BIOLOGY, 1998, 10 (05) :654-659
[4]   Determination of metalloproteinases, plasminogen-activators and their inhibitors in the synovial fluids of patients with rheumatoid arthritis during chemical synoviorthesis [J].
Blaser, J ;
Triebel, S ;
Maasjosthusmann, U ;
Romisch, J ;
KrahlMateblowski, U ;
Freudenberg, W ;
Fricke, R ;
Tschesche, H .
CLINICA CHIMICA ACTA, 1996, 244 (01) :17-33
[5]  
Bramhall SR, 1997, INT J PANCREATOL, V21, P1
[6]   Metalloproteinase inhibitors and the prevention of connective tissue breakdown [J].
Cawston, TE .
PHARMACOLOGY & THERAPEUTICS, 1996, 70 (03) :163-182
[7]   Myocardial matrix metalloproteinase activity and abundance with congestive heart failure [J].
Coker, ML ;
Thomas, CV ;
Clair, MJ ;
Hendrick, JW ;
Krombach, RS ;
Galis, Z ;
Spinale, FG .
AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY, 1998, 274 (05) :H1516-H1523
[8]   Plasminogen activators and matrix metalloproteases, mediators of extracellular proteolysis in inflammatory demyelination of the central nervous system [J].
Cuzner, ML ;
Opdenakker, G .
JOURNAL OF NEUROIMMUNOLOGY, 1999, 94 (1-2) :1-14
[9]   Anti-TNFα therapy of rheumatoid arthritis:: what have we learned? [J].
Feldmann, M ;
Maini, RN .
ANNUAL REVIEW OF IMMUNOLOGY, 2001, 19 :163-196
[10]   A quantitative structure-activity relationship study on Clostridium histolyticum collagenase inhibitors:: Roles of electrotopological state indices [J].
Gupta, SP ;
Kumaran, S .
BIOORGANIC & MEDICINAL CHEMISTRY, 2003, 11 (14) :3065-3071